Nigel Layton Partner - Head of Pharma & Life Sciences
As the Global Head of Pharma & Life Sciences and the UK Head of Investigations, Nigel can provide expertise on life sciences and pharma sector issues. Having specialised in the provision of forensic services for more than 25 years, to solicitors and corporates, Nigel can help with the following:
- Third-party due diligence
- Third-party risk management
- Third-party compliance audits
- Stakeholder mapping and community relations strategies
- Provision of strategic intelligence, consisting of market entry support and background checks
- Investigations into fraud, bribery, corruption, bullying and harassment and other issues
- Fraud prevention and awareness
Experience
Over the past thirty years, Nigel has advised many multinational companies, including leading pharma & life sciences companies, law firms and financial institutions, on a variety of matters, particularly involving bribery, corruption and fraud. Nigel has established strong relationships with our largest clients in the pharma & life sciences sector, ensuring that we deliver on complex projects and helping our clients in their pursuit of growth, efficiency, and success. He has conducted investigations into bribery, corruption, and fraud in a number of jurisdictions including all major continents of the world. He has also performed many compliance assignments covering areas such as:
- Compliance with the UK Bribery Act and FCPA
- Anti-money laundering compliance assignments
- Sanctions
- Modern slavery
- Internal audit risk assignments
Work Highlights
Nigel conducted the inquiry into alleged irregularities of transfers in 2008 for a leading sporting regulatory body. He has also conducted major confidential investigations in India, China, Russia, Kazakhstan, and Nigeria among other jurisdictions.
Nigel has conducted over 50 distributor third-party audits worldwide and many procurement fraud investigations across the globe. Nigel previously headed KPMG’s forensic practice in Russia and the CIS in 2012/13.
Want to know more?
Nigel Layton Partner - Head of Pharma & Life Sciences
Pages associated to Nigel Layton
Industries
- Why pharma and life sciences businesses shouldn’t just focus on the science
- CSDDD poised to create a trickle-down effect throughout the supply chain
- Conducting an effective internal investigation
- Anti-bribery and corruption in the sector
- Global Pharma & Life Sciences team
- Private equity and deals activity in the sector
- Getting the culture right is critical for local government to succeed in its goals
- Pharma & life sciences insights
- Fraud & corruption in the pharmaceutical industry in China
- Life sciences
- Life sciences & healthcare
Services
Insights
- What does the Budget mean for the life sciences sector in 2025?
- Is the R&D tax credit regime still fit for purpose?
- Third party risk management in pharma and life sciences – you’re only as strong as your weakest link
- Great to see you at FT Live
- What’s next for boards in the UK life sciences industry?
Who we are
This website uses cookies.
Some of these cookies are necessary, while others help us analyse our traffic, serve advertising and deliver customised experiences for you.
For more information on the cookies we use, please refer to our Privacy Policy.
This website cannot function properly without these cookies.
Analytical cookies help us enhance our website by collecting information on its usage.
We use marketing cookies to increase the relevancy of our advertising campaigns.